Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1939]

Hodgkin’s and non-Hodgkin’s lymphomas (NHL)

Dr Jose Sandoval Sus - Memorial Healthcare System, Florida, USA

Hodgkin’s and non-Hodgkin’s lymphomas (NHL) ( Dr Jose Sandoval Sus - Memorial Healthcare System, Florida, USA )

Lisocabtagene maraleucel is efficacious at treating R/R chronic lymphocytic...

Dr Tanya Siddiqi - City of Hope, Duarte, USA

Lisocabtagene maraleucel is efficacious at treating R/R chronic lymphocytic leukaemia/small lymphocytic lymphoma ( Dr Tanya Siddiqi - City of Hope, Duarte, USA )

Real-world use of brexu-cel shows benefit in R/R mantle cell lymphoma treatment

Dr Nausheen Ahmed - The University of Kansas Cancer, Kansas, USA

Real-world use of brexu-cel shows benefit in R/R mantle cell lymphoma treatment ( Dr Nausheen Ahmed - The University of Kansas Cancer, Kansas, USA )

Venetoclax and ibrutinib therapy shows favourable results in the treatment of R...

Prof Arnon Kater - Amsterdam UMC, Amsterdam, Netherlands

Venetoclax and ibrutinib therapy shows favourable results in the treatment of R/R chronic lymphocytic leukaemia ( Prof Arnon Kater - Amsterdam UMC, Amsterdam, Netherlands )

Selinexor, bortezomib and dexamethasone shows PFS benefit for multiple myeloma

Dr Maria-Victoria Mateos - University Hospital Salamanca, Salamanca, Spain

Selinexor, bortezomib and dexamethasone shows PFS benefit for multiple myeloma ( Dr Maria-Victoria Mateos - University Hospital Salamanca, Salamanca, Spain )

ADCLEC.syn1 and CD33-CARS in humanised acute myeloid leukaemia models shows...

Dr Sascha Haubner - Memorial Sloan Kettering Cancer Center, New York City, USA

ADCLEC.syn1 and CD33-CARS in humanised acute myeloid leukaemia models shows promising efficacy ( Dr Sascha Haubner - Memorial Sloan Kettering Cancer Center, New York City, USA )

Ide-cel significantly prolongs PFS for r/r multiple myeloma versus standard...

Dr Krina Patel - MD Anderson Cancer Center, Houston, USA

Ide-cel significantly prolongs PFS for r/r multiple myeloma versus standard regimens ( Dr Krina Patel - MD Anderson Cancer Center, Houston, USA )

A randomised trial of the FLT3 inhibitor gilteritinib as post-transplant...

Dr Mark Levis - Johns Hopkins Sidney Kimmel Comprehensive Cancer Center...

A randomised trial of the FLT3 inhibitor gilteritinib as post-transplant maintenance for FLT3-ITD AML ( Dr Mark Levis - Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA )

Single infusion of cilta-cel sees longer median PFS than any previously...

Dr Nikhil Munshi - Dana-Farber Cancer Institute, Boston, USA

Single infusion of cilta-cel sees longer median PFS than any previously reported therapy in heavily pretreated RRMM ( Dr Nikhil Munshi - Dana-Farber Cancer Institute, Boston, USA )

Atezolizumab, obinutuzumab and venetoclax combination is active and leads to...

Prof Anna Maria Frustaci - Niguarda Ca’ Granda Hospital, Milan, Italy

Atezolizumab, obinutuzumab and venetoclax combination is active and leads to durable remissions in previously untreated DLBCL-RS ( Prof Anna Maria Frustaci - Niguarda Ca’ Granda Hospital, Milan, Italy )

Addition of blinatumomab to mini-hyper-CVD and inotuzumab improves outcomes in...

Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA

Addition of blinatumomab to mini-hyper-CVD and inotuzumab improves outcomes in R/R ALL ( Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA )

Chemotherapy-free combination of ponatinib and blinatumomab results in high...

Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA

Chemotherapy-free combination of ponatinib and blinatumomab results in high rates of CMR and NGS MRD negativity in Ph positive ALL ( Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA )

More from ecancer